Artificial Intelligence
Leading Parkinson’s Researcher Dr. Robert A. Hauser Joins Pharmather as Scientific Advisor
TORONTO, Oct. 29, 2020 (GLOBE NEWSWIRE) — Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce the appointment of Dr. Robert A. Hauser, MD, MBA, as a scientific and clinical advisor to the Company. Dr. Hauser currently serves as Professor of Neurology and Director of the University of South Florida Parkinson’s Disease and Movement Disorders Center.
“We would like to welcome Dr. Hauser as a scientific and clinical advisor to our Company and we look forward to his contributions as we continue to advance the clinical development of ketamine in the treatment of levodopa-induced dyskinesia associated with Parkinson’s Disease,” said Fabio Chianelli, CEO of Pharmather. “Dr. Hauser brings invaluable guidance and extensive clinical experience having served as Site Principal Investigator on over 100 clinical trials involving Parkinson’s Disease. With the addition of Dr. Hauser and our recent application for FDA orphan drug designation, we are building a solid foundation to advance ketamine for Parkinson’s Disease in a Phase 2 clinical study in an expeditious manner.”
“There is a significant unmet medical need for new treatments in Parkinson’s Disease,” said Dr. Hauser. “Pre-clinical studies and a patient case series suggest that ketamine has the potential to ameliorate levodopa-induced dyskinesia associated with Parkinson’s Disease. I look forward to working with the Pharmather team in their pursuit to advance this program to human clinical studies.”
Dr. Robert Hauser is Professor of Neurology at the University of South Florida College of Medicine, in Tampa, Florida. He serves as Director of the USF Parkinson’s Disease and Movement Disorders Center, a Parkinson Foundation Center of Excellence. Dr. Hauser earned a medical degree from Temple University School of Medicine, in Philadelphia, Pennsylvania, and completed neurology training at the Eastern Virginia Graduate School of Medicine, in Norfolk, Virginia. Dr. Hauser completed a fellowship in Movement Disorders at the University of South Florida and became Center Director in 1994. Dr. Hauser has authored or co-authored more than 300 peer-reviewed publications and is one of the world’s most cited Parkinson’s Disease investigators. He is Past Chairman of the Interventional Neurology Section of the American Academy of Neurology, has served on the executive committee of the Parkinson Study Group, and was a member of the steering committee for the NIH sponsored Neuroprotective Exploratory Trials in Parkinson’s Disease program (NET-PD). Dr. Hauser lectures frequently at scientific meetings and served as Chairman of the 2009 World Federation of Neurology International Congress on Parkinson’s Disease and Related Disorders. He has extensive expertise in clinical trial design and execution. Outcome measures that he developed have become the gold standard for use in clinical trials.
Dr. Hauser’s research focuses of the development of new therapies for Parkinson’s Disease and other Movement Disorders.
Promising Results with Ketamine in Parkinson’s Disease
Ketamine is an FDA-approved drug with a known safety profile. Prior clinical reports suggest that low-dose ketamine infusions are well tolerated and can improve pain and depression, both often comorbidities in Parkinson’s Disease patients.
Inventors Dr. Scott Sherman and Dr. Torsten Falk, both associate professors at the University of Arizona College of Medicine – Tucson, are working with Tech Launch Arizona to patent the results from preclinical data and five case studies in Parkinson’s Disease patients showing that low-dose sub-anesthetic ketamine infusion indicates tolerability, safety and the potential of long-term therapeutic benefit to reduce Levodopa-induced dyskinesia, improve on time, and reduce depression.1–5
The global Parkinson’s Disease market is expected to grow from USD $5 billion in 2019 to USD $7.5 billion by the end of 20256 and it is estimated that the potential market opportunity for LID-PD to be over USD $3 billion in the U.S. alone.
About Parkinson’s Disease
Parkinson’s Disease is a debilitating disorder that affects over 1 million people in the U.S. and more than 7 million people worldwide. There is currently no cure for Parkinson’s Disease, although some drug combinations are used to treat the disease symptoms.
Levodopa is the gold standard for Parkinson’s Disease treatment but features significant drawbacks, including the major side effect of dyskinesia and a loss of effectiveness over time. Approximately 50% of patients with Parkinson’s Disease will develop Levodopa-induced dyskinesia 4-5 years after the initiation of levodopa therapy, and this number rises to 80% after 10-12 years of levodopa treatment. LID may interfere with motor function, cause or aggravate pain and is known to worsen the quality of life significantly.
Individuals with Parkinson’s Disease may experience a host of non-motor symptoms such as autonomic dysfunction, psychiatric (depression), cognitive and sensory symptoms (pain). Therefore, there is an urgent need for alternative treatments and has been identified by the regulatory authorities, patient advocacy groups such as Michael J. Fox Foundation, and key opinion leaders as a substantial unmet medical need.
About Pharmather Inc.
Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. Pharmather repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Our team includes world-class strategic partners, advisors and a strong leadership team with a proven track record of success in drug development, business development and capital markets. Our goal is to advance the development of panaceAI™, our drug repurposing artificial intelligence platform, and our clinical product pipeline with ketamine and psilocybin in the treatment of Parkinson’s Disease, depression, pain, traumatic brain injury and stroke. Learn more at: pharmather.com and follow us on Facebook, Twitter and LinkedIn.
For more information, please contact:
Fabio Chianelli
Chief Executive Officer
Pharmather Inc.
Tel: 1-888-846-3171
Email: [email protected]
Website: www.pharmather.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to U.S. Food and Drug Administration (“FDA”) approval under an Orphan Drug Designation (“ODD”) and investigational new drug (“IND”) to conduct a Phase II clinical study, market opportunities in Parkinson’s Disease and levodopa-induced dyskinesia associated with Parkinson’s Disease (“LID-PD”), ketamine programs towards human clinical studies under the FDA regulatory pathway and product developments. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of August 30, 2020 (“MD&A”), dated October 1, 2020, which is available on the Company’s profile at www.sedar.com.
References:
1. UA Clinical Trial to Repurpose Ketamine for Parkinson’s Patients.
2. US20190060254A1— Compositions and methods for treating motor disorders.
3. Bartlett, et al, 2020. Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. Experimental Neurology. Volume 333.
4. Bartlett, M.J., Joseph, R.M., LePoidevin, L.M., Parent, K.L., Laude, N.D., Lazarus, L.B., Heien, M.L., Estevez, M., Sherman, S.J., Falk, T., 2016. Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model.
5. Sherman, S.J., Estevez, M., Magill, A.B., Falk, T., 2016. Case reports showing a long-term effect of subanesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias. Case Rep. Neurol. 8, 53–58.
6. 360iResearch 2020.
Artificial Intelligence
New first of its kind UK legal-tech recruitment platform aims to put an end to overseas worker scams
Unique UK-based legal technology platform, Immpact, helps unite the global talent market to fulfil UK skills shortages across healthcare, construction, engineering, life sciences and hospitality Immpact directly connects employers, recruiters and regulated legal experts with pre-qualified global talent – and aims to help eradicate profiteering job scammersREADING, England, May 28, 2024 /PRNewswire/ — A unique new legal-tech recruitment platform has launched in the UK to help put an end to overseas worker scams and directly connect UK employers and recruiters with pre-qualified overseas global talent. Immpact will help fulfil acute skills shortages across sectors including healthcare, construction, engineering, life sciences and hospitality, while ensuring full legal Home Office compliance.
The launch of Immpact follows over two years of advanced legal-tech development. Using the immigration law expertise of Founder and Managing Director, Jonathan Beech, and his team of specialists, the platform will help unite a previously disconnected global talent market with under-resourced UK employers and transform global workplace migration. Immpact has also been developed through discussions with hundreds of employers, industry bodies and overseas talent.
With job scams – from fake jobs to illegal fees for sponsor licences – ongoing, particularly in the social and healthcare sector, Immpact will ensure only pre-qualified talent, employers and recruitment firms are placed on its platform following stringent multi-layer checks. This will ensure that all jobs and talent are qualified and genuine along with thoroughly regulated employers and recruiters, to provide a global marketplace for talent.
Jonathan Beech, Founder and Managing Director of Immpact, said: “Through my existing business running Migrate UK, I’m acutely aware of the issues that UK employers and recruiters are having in trying to fulfil talent shortages across sectors such as care, healthcare and life sciences. I also regularly hear terrible stories of genuine overseas job hunters being ripped off in their home countries or the UK by job scammers, often running to thousands of pounds.
“I knew there had to be a better way to match pre-qualified overseas talent with genuine work opportunities and responsible UK employers – effectively a ‘talent’ match-making site which is designed to eradicate scammers to provide a global, trusted marketplace for talent.”
Following the latest government immigration rule changes, overseas recruitment costs are continuing to rise for businesses struggling with talent shortages. From 4 April 2024, the minimum salary for entering the new skilled visa worker route for the first time increased by 48%, from £26,200 to £38,700 a year. There are different rates for those already holding a skilled worker certificate of sponsorship prior to this date and discounts are available for key shortage roles on the Immigration Salary List (ISL).
Immpact will benefit employers and recruiters by saving them time and money. Working with recruitment experts to analyse existing overseas recruitment workflows, Immpact has calculated that it will save 50% of the time involved in managing overseas recruitment, helping to cut down the time-consuming filtering of applications traditionally needed.
For employers traditionally looking to recruit overseas applicants, previous data from industry recruitment software specialists show that 30% of overseas applications are rejected as they do not have the right to work, while 64% are rejected due to CVs being unclear or requirements not being met. This leaves just 6% of applications remaining, which results in about 2% then being interviewed. Immpact will automatically present only suitable pre-qualified applications to employers or recruiters, eradicating wasted time on unsuitable or unqualified applicants.
Beech continues: “Following thousands of hours of development and utilising the latest advanced technology which can adapt to evolving Home Office requirements and procedures, we’re proud to launch Immpact. Our unique new platform takes care of the entire process – from pre-qualifying processes, searching and shortlisting, down to arranging interviews, successful appointments, onboarding, the provision of regular content and guidance, and access to regulated immigration legal professionals.
“Our new technology will transform global migration for both UK organisations and businesses struggling to recruit and global talent looking to work in the UK. Immpact has been thoroughly tested at every stage and is both user-friendly and, crucially, compliant, so qualified overseas applicants and UK employers and recruiters can be confident that only genuine UK jobs and overseas applicants match and proceed. Quite simply, we want Immpact to simplify the whole migration process by putting the right talent in the right place at the right time, and for UK employers to fulfil critical talent shortages which will help them not only survive, but thrive.”
The platform has a free trial or low-cost subscriber options for search-matching and more for employers and recruiters. For talent, the platform has zero costs for creating a profile, using the pre-qualifying tools or searching for opportunities. For further information visit www.immpact.ai.
Photo – https://mma.prnewswire.com/media/2421643/Founder_and_Managing_Director_Immpact.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/new-first-of-its-kind-uk-legal-tech-recruitment-platform-aims-to-put-an-end-to-overseas-worker-scams-302155226.html
Artificial Intelligence
Bluecrux supports Sanofi in harnessing AI to transform supply chains for tomorrow
BARCELONA, Spain, May 28, 2024 /PRNewswire/ — Sanofi is all in on AI and wants to become the first biopharma company powered by AI at scale. The company is using AI to chase the miracles of science by accelerating drug discovery, enhancing clinical trial design and improving the manufacturing and supply of medicines and vaccines to get them to patients in need faster. Bluecrux’s digital supply chain twin technology, Axon, plays a critical role in Sanofi’s digital supply chain transformation.
Delivering miracles of science to patients
The company is paving the way as a leader in innovation among pharma companies with its broad AI implementation, enhancing operational capabilities across various domains of the business. Sanofi’s ambition is particularly pronounced in its supply chain strategy, in which AI is pivotal in “delivering miracles of science to patients.” With greater efficiency, the company can redirect savings toward R&D and medicine development.
Bluecrux’s Axon plays a critical role in Sanofi’s digital supply chain transformation. Axon is a digital twin that integrates and harmonizes all Sanofi’s data systems into ONE single digital value chain model. This allows for a comprehensive understanding of Sanofi’s supply chain operations from start to finish. “The end-to-end visibility of our supply chain value stream has already helped us identifying large opportunities to improve inventory and process cycle times that will ultimately get our products to patients faster”, says Leif Skibsted Jakobsen, Head of Digital Supply Chain Sanofi. “We have put in place a structured process for implementing these opportunities and with Axon we are also able to validate the results.”
“Axon is an important puzzle piece in supporting Sanofi’s aims to create an E2E-connected, data driven and digitally accelerated supply chain”, adds Valerie Vandenbroucke, VP for Axon Technology Bluecrux. “Although the use of the platform is already transformational, the journey has just begun, with many more breakthroughs on the horizon.”
Sanofi and Bluecrux at Gartner Barcelona
At the upcoming Gartner Supply Chain Symposium EMEA conference in Barcelona (June 10-12), Bluecrux will join Sanofi in a special session that will delve into the transformative power of artificial intelligence in the realm of supply chain management. Valérie Vandenbroucke, VP of Bluecrux’s Axon Technology, and Sanofi’s Leif Skibsted Jakobsen will be co-presenting.
During the session, attendees will gain insights into how Sanofi has harnessed AI to meet and exceed its business objectives. It will explore how Sanofi translated its vision into a practical roadmap and how AI can catalyze a true transformation in supply chain management, including helping the company become an E2E-connected, data-driven and digitally accelerated supply chain.
About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
About Bluecrux
Founded in 2011, Bluecrux is a leading value chain technology and consulting company, assisting global companies to navigate and improve their supply chains. The company’s global reach and innovative technologies, Binocs and Axon, reflect its goal to combine expertise with technology, turning challenges into opportunities.
View original content:https://www.prnewswire.co.uk/news-releases/bluecrux-supports-sanofi-in-harnessing-ai-to-transform-supply-chains-for-tomorrow-302156155.html
Artificial Intelligence
Slovenian Tourist Board Unveils Innovative Projects to Enhance Tourism and Sports Visibility: Audio Stories, AI-Powered Virtual Assistant, and “Slovenia – Sports Destination” Website
LJUBLJANA, Slovenia, May 28, 2024 /PRNewswire/ — Slovenia is a land of countless natural beauties, cultural treasures, top health and wellness resorts and superb gastronomy, which the Slovenian Tourist Board aims to showcase to visitors in an innovative and attractive way. To achieve this, the Board continually analyzes current marketing trends and develops projects designed to excite tourists, spark their curiosity and inspire them to explore further.
By staying at the forefront of marketing strategies, the Slovenian Tourist Board ensures that the country’s unique attractions are presented in the most engaging and appealing manner possible. The most recent projects to boost Slovenia’s visibility include three new projects: Sounds Like Slovenia, a series of audio stories, an AI-powered virtual assistant named Alma on slovenia.info and the “Slovenia – Sports Destination” website.
More
Meet Alma, an AI-powered virtual assistant
Alma, named after the adventurous traveller and writer Alma M. Karlin, operates using advanced AI technology, filtering content to suit user interests. She sources reliable information from the slovenia.info database and over 50 verified websites of Slovenian tourist destinations and providers. As one of the first AI assistants in Slovenian tourism, and among the few AI assistants integrated in national tourism organizations’ websites in Europe, Alma positions slovenia.info as a reliable source of information and inspiration for international visitors.
More
Slovenia – Sports Destination Website
The Slovenia–Sports Destination website serves as a comprehensive resource for organizing sports activities and events, conferences, rehabilitation and inspiration, available in both Slovenian and English. Sports agencies, clubs, and event organizers can use the portal to connect directly with relevant partners in Slovenia. The website also provides direct contacts for specialized sports agencies and federations, assisting with the organization of preparatory matches and other logistical needs. Information on sports accommodations is also available.
More
Sounds Like Slovenia
Thematic playlists on Spotify and sound stories on slovenia.info provide an immersive audio experience of Slovenia’s landscapes and cultural offerings. Themes are categorized into five categories: the Sounds of Nature, Thrilling Outdoor Adventures, Cities and Culture, Health and Well-Being, and Gastronomy. Crafted for the global digital campaign, the audio list aims to captivate travelers worldwide.
More
Together, these projects demonstrate Slovenia’s dedication to innovation and sustainability in tourism, offering visitors unforgettable experiences in this vibrant European destination with a green heart.
Photo: https://mma.prnewswire.com/media/2422785/Sounds_like_slovenia.jpg
View original content:https://www.prnewswire.co.uk/news-releases/slovenian-tourist-board-unveils-innovative-projects-to-enhance-tourism-and-sports-visibility-audio-stories-ai-powered-virtual-assistant-and-slovenia—sports-destination-website-302156165.html
-
Artificial Intelligence4 days ago
Titans of Tech: GP Bullhound releases its annual report on the European tech ecosystem
-
Uncategorized4 days ago
GienTech Hosted the “2024 GienTech Digital Transformation Conference” to Promote Overseas Collaborative Ecosystem Development
-
Uncategorized4 days ago
Hyreo ushers in a New Dawn for Recruitment Technology with Hyreo Labs
-
Artificial Intelligence4 days ago
Bybit Web3 Announces Upcoming IDO for Aperture Finance, Simplifying Web3 Finance
-
Artificial Intelligence6 days ago
HONOR Unveils Four-Layer AI Architecture and Forges Ahead with Google Cloud for More AI Experiences at VivaTech 2024
-
Artificial Intelligence4 days ago
Overseas Expansion Strategy of K-OTT Introduced in France, KOCCA holds the ‘2024 Korea-France Content Forum’
-
Artificial Intelligence4 days ago
Northern Data Group’s Peak Mining, announces purchase of a second 300MW data center location in Corpus Christi, Texas
-
Artificial Intelligence4 days ago
IoT Node and Gateway Market worth $604.7 billion by 2029 – Exclusive Report by MarketsandMarkets™